TNFRSF17 and hematologic disorder: Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in treating hematologic malignancies and has been approved by the FDA for CD19-targeted and B-cell maturation antigen (BCMA)-targeted CARs [1, 2].